Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective.

As A(H1N1) influenza enters the post-pandemic phase, health authorities around the world are reviewing the response to the pandemic. To ensure this process enhances future preparations, it is essential that perspectives are included from all relevant stakeholders, including vaccine manufacturers. This paper outlines the contribution of R&D-based influenza vaccine producers to the pandemic response, and explores lessons that can be learned to improve future preparedness.

Influenza vaccine supply: building long-term sustainability.

Influenza represents a public health paradox. The virus is responsible for significant death, disease and economic loss. However, despite the availability of safe and efficacious vaccines, uptake is poor.